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Background: We analyzed the performance of a novel ENA screening chemiluminescent immunoassay (CIA)
and the conﬁrmation QUANTA Flash tests.
Methods: Sera (n = 1079) from patients referred to a rheumatology clinic were screened by QUANTA Flash
ENA7 (INOVA Diagnostics). All positive (n = 89) and a matched control group (n = 90) were reﬂexed for
autoantibodies to the individual antigens. Moreover, sera from patients with systemic lupus erythematosus
(SLE, n = 252), systemic sclerosis (SSc, n = 64), polymyositis/dermatomyositis (PM/DM, n = 72), Sjögren's
syndrome (SjS, n = 39) as well as disease controls (n = 605) were tested by ENA7 CIA and by Quanta Lite
ENA6 ELISA (INOVA).
Results: 89/1079 (8.3%) samples were ENA7 CIA positive with the following reactivity proﬁle: RNP (36.0%),
Sm (13.5%), Scl-70 (9.0%), Jo-1 (0.0%), Ro60 (44.9%), Ro52 (39.3%) and SS-B (24.7%). In the negative group,
the reactivity proﬁle was: RNP (1.1%), Sm (1.1%), Scl-70 (2.2%) and 0.0% for Jo-1, Ro60, Ro52 and SS-B. The
positive/negative/total agreements (ENA7 CIA vs. conﬁrmation assays) were 95.3%/91.5%/93.3%. The sensitiv-
ity of the ENA7 CIA was 62.3% in SLE, 54.7% in SSc, 92.3% in SjS, 50.0% in PM/DM, and 61.8% in the total sys-
temic autoimmune rheumatic disease (SARD) population (speciﬁcity 95.0%).
Conclusion: The QUANTA Flash ENA7 CIA is a reliable screening test.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Autoantibodies targeting extractable nuclear antigens (ENA) are
hallmarks in the diagnosis of systemic autoimmune rheumatic dis-
eases (SARD) such as systemic lupus erythematosus (SLE) or systemic
sclerosis (SSc) [1]. The primary antigenic targets of anti-ENA antibod-
ies are U1-ribonucleoproteins (RNP), Sm (Smith antigen), Scl-70
(topoisomerase I), Jo-1, Ro60 (SS-A), Ro52 (TRIM21) and SS-B (La).s; AMR, analytical measuring
ical and Laboratory Standards
noassays; PBC, primary biliary
, systemic autoimmune rheu-
Sjögren's syndrome; SSc, sys-
Old Grove Rd., San Diego, CA
: +1 858 586 9911.
.job@web.de (M. Mahler).
.V. Open access under CC BY license.Not all of those antibodies are speciﬁc for a particular disease, but are
useful to help ruling in or out SARD [1]. Among the disease speciﬁc
antibodies, anti-Scl-70 are speciﬁc for SSc [2], anti-Jo-1 for polymyo-
sitis (PM) [1] and anti-Sm antibodies for SLE [1,3]. Among the most
common antibodies are antibodies to Ro52, Ro60 and SS-B which
therefore deserve special attention and careful evaluation. Historically,
anti-Ro52 and anti-Ro60 antibodies have been detected and reported
simultaneously. However, recent data suggested that both the cellular
function and the clinical association of anti-Ro52 and anti-Ro60 anti-
bodies are signiﬁcantly different [4]. Anti-Ro60 antibodies are asso-
ciated with SLE and SjS whereas anti-Ro52 antibodies can be found
in various disease conditions including PM and SSc [5] but also in
several forms of lung disease associated with autoimmunity [6]. Of
high importance, about 20% of anti-Ro52/anti-Ro60 antibodies can
be missed when tested using a blend of the two antigens [4]. Besides
the diagnostic value of antibodies to Ro52, Ro60 and SS-B, it has been
shown that those antibody speciﬁcities can precede the clinical onset
of SLE for many years [7]. In addition to SARD, previous studies have
reported autoantibodies to ENA in PBC [1,8]. Several methods have
been developed and used for the detection of anti-ENA antibodies
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says (ALBIA) [10–13] and protein arrays [14]. During the last years, the
chemiluminescence technology, which has been used for clinical chem-
istry for a long time, has been applied for autoantibody testing [15].
2. Materials and methods
2.1. Sera
Sera (n = 1079) frompatients referred to a rheumatology clinicwere
screened for anti-ENA7 antibodies by QUANTA Flash ENA7 (INOVA
Diagnostics, Inc., San Diego, CA). All positive samples (n = 89) and ap-
proximately the same number of randomly selected negative samples
(n = 90) were reﬂexed for autoantibodies to the individual antigens
(RNP, Sm, Scl-70, Jo-1, Ro60, Ro52 and SS-B) using the QUANTA Flash as-
says. To compare the clinical performance of the QUANTA Flash ENA7
CIA to a predicate device, sera from patients with SLE (n = 252), SSc
(n = 64), PM/DM (n = 72), and SjS (n = 39), as well as various disease
controls (n = 605, for details see the Results section) were tested by
QUANTA Flash ENA7 CIA and by Quanta Lite ENA6 ELISA (INOVA; RNP,
Sm, Scl-70, Jo-1, Ro60, Ro52 and SS-B). Additionally, sera from patients
with PBC (n = 52)were screened by bothmethods, butwere not includ-
ed as part of the disease controls for analysis since PBCpatients are known
to have ENAs. A list of the disease cohorts and controls can be found in
the Results section. To verify the speciﬁcity of the Scl-70 assay, various
disease controls were tested (n = 628). The diagnoses were established
as described before [3] or according to the standard disease criteria.
This study meets and is in compliance with all ethical standards in
medicine. Patient identity was not disclosed and the data was anony-
mously used in accordance with the latest version of the Helsinki
Declaration of human research ethics.
2.2. QUANTA Flash(R) assays
The QUANTA Flash assays (INOVA Diagnostics Inc., San Diego, CA)
are novel CIA that are currently used on the Bio-Flash® instrument
(Biokit s.a., Barcelona, Spain), a fully automated chemiluminescent
immuno-analyzer. The principle of the Bio-Flash system has recently
been described [15]. The QUANTA Flash assays used in this study
were developed using native or recombinant antigens (INOVA Diag-
nostics, see Table 1) coated onto paramagnetic beads. Prior to use,
the lyophilized beads are resuspended using the resuspension buffer.
A patient serum sample is pre-diluted with the Bio-Flash® sample
buffer in a small disposable plastic cuvette. Small amounts of the di-
luted patient serum, the beads, and the assay buffer are all combined
into a second cuvette, mixed, and then incubated for 9.5 min at 37 °C.
The magnetized beads are sedimented using a strong magnet in the
washing station and washed several times followed by addition of
isoluminol conjugated anti-human IgG and again incubated 9.5 min
at 37 °C. The magnetized beads are sedimented and washed repeat-
edly. The isoluminol conjugate is oxidized when sodium hydroxide
solution and peroxide solutions (“triggers”) are added to the cuvette,
and the ﬂash of light produced from this reaction is measured as rel-
ative light units (RLUs) by the Bio-Flash® optical system. The RLUs
are proportional to the amount of isoluminol conjugate that isTable 1
Antigen composition of QUANTA Flash ENA7 and QUANTA Lite ENA6.
Antigen QUANTA Flash ENA7 QUANTA Lite ENA6
RNP Native puriﬁed Native puriﬁed
Sm Native puriﬁed Native puriﬁed
SS-A Ro60 Recombinant, insect cells Native puriﬁed
SS-B La Recombinant, insect cells Native puriﬁed
Ro52 Recombinant, insect cells Recombinant, insect cells
Scl-70 Recombinant, insect cells Native puriﬁed
Jo-1 Recombinant, insect cells Native puriﬁedbound to the human IgG, which is in turn proportional to the amount
of autoantibodies bound to the antigen on the beads. The Bio-Flash
system also allows the customer the option to reﬂex the individual
assays of a screening test such as the QUANTA Flash ENA7.
2.3. Quanta Lite assays
Quanta Lite ENA6 was used as a comparator method. This ELISA
contains the same number of antigens as the QUANTA Flash ENA7.
Historically, Ro52 and Ro60 were called SS-A [4] and therefore
counted as one antigen when the Quanta Lite ENA6 was developed.
The antigen composition and sources are shown in Table 1. The
assay was performed according to the direction of use.
2.4. Precision and linearity studies
Precision and linearity of the assays were veriﬁed by performing
the required testing according to the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines. For the precision study, the within
run, between day, between run, and total precision were determined
by running 2 aliquots of the precision samples twice a day in random
order, with a minimum of 2 h between each run. The samples were
run on the same instrument for each assay and repeated for at least
20 days, according to CLSI guideline EP5-A2. Linearity testing was
performed according to CLSI guideline EP6-A (Vol. 23, No. 16),
which involved diluting several high titer sera in a serial dilution
scheme to span the analytical measuring range (AMR) for each assay.
2.5. Generation of mono-speciﬁc samples (Jo-1)
Seven samples with high titers of Jo-1 antibodies were diluted in
normal serum to yield negative or low positive results for all other auto-
antibodies to antigens contained in the ENA7 Screen. Those samples
were then used to analyze the sensitivity of QUANTA Flash ENA7 for Jo-1.
2.6. Statistical analyses
The data were statistically evaluated using the Analyse-it Software
(ver 1.62; Analyse-it Software, Ltd., Leeds, UK). Linearity results were
analyzed by linear regression analysis, and slope, intercept and R2
values were calculated. Chi-square, Spearman's correlation and Cohen's
kappa agreement tests were carried out to analyze the agreement be-
tween portions and p b 0.05 was considered signiﬁcant. Receiver-
operating characteristics (ROC) analysis was used to analyze the
discriminatory ability of different immunoassays.
3. Results
3.1. Precision and linearity
Precision study results for all QUANTA Flash CIAs are shown in
Table 2. The total precision for all assays varied between 3.8 and 13.8%.
The linearity study results are tabulated in Table 3 for all QUANTA Flash
CIA assays. All assays demonstrated linearity over the AMR.Table 2
Precision data of the QUANTA Flash CIA assays.
No. of samples Within run Between-day Between-run Total
ENA7 8 1.8–4.3% 2.6–6.3% 0.0–2.6% 4.0–7.1%
RNP 7 3.4–4.8% 3.0–9.3% 0.0–4.5% 4.8–10.8%
Sm 5 5.3–9.7% 2.7–5.8% 0.5–7.1% 8.3–11.5%
Ro60 9 2.9–5.8% 0.0–2.6% 2.9–9.6% 3.8–10.5%
Ro52 6 4.1–6.9% 6.2–11.6% 0.0–4.1% 9.8–12.5%
SS-B 7 3.7–9.3% 7.2–9.9% 1.8–6.8% 9.7–13.8%
Scl-70 7 2.2–4.5% 0.0–2.6% 1.9–4.2% 4.3–5.0%
Jo-1 9 2.9–5.0% 4.7–6.8% 0.0–3.0% 6.2–8.0%
Table 3
Linearity data of the QUANTA Flash CIAs.
Assay AMR (CU) Test range (CU) Slope (95% CI) Y-intercept (95% CI) R2 Percent recovery
ENA7 3.6–429.4 N.A. N.A. N.A. N.A. N.A.
RNP 3.5–643.8 3.8 to 649.0 1.00 (1.00 to 1.01) −4.28 (−7.14 to −1.42) 1.00 85.0–109.4%a
Sm 3.3–693.5 3.3 to 742.6 1.00 (0.98 to 1.01) 0.02 (−3.98 to 4.02) 0.99 88.0–112.8%
Ro60 4.9–1374.8 3.9 to 1370.1 1.00 (0.98 to 1.10) 1.69 (−4.58 to 7.95) 1.00 89.4–109.0%
Ro52 2.3–1685.3 0.6 to 1758.6 1.03 (1.02 to 1.04) 3.61 (−0.86 to 8.08) 1.00 94.7–118.4%a
SS-B 3.3–1706.8 3.4 to 1828.1 1.03 (1.01 to 1.04) 3.44 (−2.72 to 9.60) 0.99 91.3–119.6%a
Scl-70 3.8–969.8 2.1 to 1476.0 1.03 (1.02 to 1.03) −1.29 (−4.78 to 2.19) 1.00 90.3–118.9%
Jo-1 2.2–1147.2 1.4 to 1203.6 0.99 (0.99 to 1.00) −2.23 (−4.43 to −0.03) 1.00 89.9–118.0%
NA = not applicable since qualitative assay; AMR = analytical measuring range.
a Or less than 2 units difference.
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A total of 89/1079 (8.3%) samples were positive by QUANTA Flash
ENA7 CIA (Fig. 1). Of those, the prevalence of autoantibodies to the
individual antigens was: RNP (36.0%), Sm (13.5%), Scl-70 (9.0%),
Jo-1 (0.0%), Ro60 (44.9%), Ro52 (39.3%) and SS-B (24.7%) (Fig. 2). In
the QUANTA Flash ENA7 CIA negative group, the prevalence of auto-
antibodies to the individual antigens was: RNP (1.1%), Sm (1.1%),
Scl-70 (2.2%), Jo-1 (0.0%), Ro60 (0.0%), Ro52 (0.0%) and SS-B (0.0%).
The positive, negative and total agreement between the QUANTA Flash
ENA7 Screen and the QUANTA Flash conﬁrmation assays were 95.3%,
91.5% and 93.3%, respectively. All four QUANTA Flash ENA7 negative,
conﬁrmation assay positive samples were negative by ELISA. Since the
two ENA7 negative Scl-70 positive patients had no evidence of SSc
(analyzed by chart review; one patient had a diagnosis of psoriatic
arthritis, HLA B27-negative; the other patient had ankylosing spondylitis
with peripheral joint involvement and Psoriasis, HLA B27-positive), weScreening
sampl
QUANTA
EN
89 QUANTA Flash
ENA7 positive
Testing of 89 ENA7
positives by
individual QUANTA
Flash assays
8 negative for all
antibodies  by 
QUANTA Flash 
assays
81 positive for ≥ 1
antibody by 
QUANTA Flash 
assays
Fig. 1. Referral study. A total of 1079 samples were screened for anti-ENA antibodies by Qua
samples (n = 90) were tested for the individual antibodies. In 8 of the positive samples no
reactivity to at least on individual component.screened various disease cohorts for anti-Scl-70 antibodies and found a
speciﬁcity of 98.7% (Fig. 3).3.3. Disease cohorts
A summary of the disease cohorts and the prevalence of ENA autoan-
tibodies using both assaymethods can be found in Table 4. In the clinical-
ly deﬁned disease cohorts, the sensitivities of QUANTA Flash ENA7 CIA/
Quanta Lite ENA6 ELISA were 62.3%/61.5% for SLE, 54.7%/57.8% for SSc,
50.0%/55.6% for PM/DM, 92.3%/89.7% for SjS and 61.8%/62.5% for SARD
combined, respectively. Screening of sera from PBC patients resulted in
19.2%/11.5% prevalence for the ENA7 CIA and ENA6 ELISA, respectively.
The speciﬁcities were 95.0% for QUANTA Flash and 93.7% for Quanta
Lite. Receiver operating characteristic analysis for QUANTA Flash ENA7
CIA/Quanta Lite ENA6 ELISA showed area under the curve values of
0.866/0.877 (SLE vs. controls), 0.812/0.871 (SSc vs. controls), 0.750/ of 1079 
es by 
 Flash 
A7
990 QUANTA Flash
ENA7 negative
Testing of 90 ENA7
negatives by
individual QUANTA
Flash assays
4 positive for ≥ 1
antibody  by 
QUANTA Flash 
assays
86 negative by all
QUANTA Flash
assays
nta Flash ENA7. The positive (n = 89) and approximately the same number of negative
individual speciﬁcity could be found. Vice versa, 4 of the ENA negative samples showed
Fig. 2. Prevalence a.) and titers b.) of anti-ENA antibodies in Quanta Flash ENA7 Screen positive (n = 89) and negative samples (n = 90). Results for antibodies to Sm, RNP, Ro60,
Ro52, SS-B, Scl-70 and Jo-1 in relation to the ENA7 results are shown.
144 C. Bentow et al. / Clinica Chimica Acta 424 (2013) 141–1470.798 (PM/DM vs. controls), 0.966/0.967 (SjS vs. controls), 0.617/0.562
(PBC vs. controls), and 0.847/0.871 (SARD vs. controls), respectively.
3.4. Validation of QUANTA Flash ENA7 for Jo-1
Since anti-Jo-1 antibodies are rare our referral cohort did not include
any Jo-1 positive sample. Therefore we studied the performance for
anti-Jo-1 antibodies using mono-speciﬁc samples. Seven samples with
high titer anti-Jo-1 antibodies were diluted in normal serum and tested
on the ENA7 and for the individual antibodies. Two out of the seven
samples were mono-speciﬁc for anti-Jo-1 antibodies (with low titers)
and yielded positive results using the ENA7 screen (66.0 CU and 67.3
CU). The ﬁve remaining samples showed reactivity not only to Jo-1,
but also to Ro52 as expected [16] and were highly positive using the
ENA7 screen (85.9 CU, 110.9 CU, 109.2 CU, 234.1 CU and 148.3 CU).
4. Discussion
The detection of anti-ENA antibodies is important to help in the
diagnosis of SARD [1]. In recent years, several new methods for the
detection of anti-ENA antibodies have been developed and commer-
cialized with special focus on automation and ease of use [17]. How-
ever, since reliable detection of autoantibodies should still be the
most desirable goal, careful veriﬁcation and validation of the assay
performance are mandatory. Consequently, we undertook this studyto analyze the performance characteristics of QUANTA Flash ENA7
and the conﬁrmation assays.
In our referral cohort, we found a good agreement between the
QUANTA Flash ENA7 and the conﬁrmatory assays (93.3%). It is desir-
able that screening assays are more sensitive than conﬁrmatory tests.
In keeping with this concept, we found eight ENA7 screen positive,
but conﬁrmatory assay negative specimens. Only four samples that
were negative on the screening test showed reactivity to at least
one of the individual antigens and all of them had very low titers.
This demonstrates that the QUANTA Flash ENA7 efﬁciently detects
almost all antibodies. However, based on the absence of anti-Jo-1 anti-
bodies in our referral cohort, further studies are needed to analyze the
agreement for Jo-1.
Although the ENA7 CIA and the ENA6 ELISA use different sources
of antigens (recombinant vs. native for Ro60, SS-B, Scl-70), the
results are very similar. During the last decade, signiﬁcant improve-
ments have been made in recombinant protein technology [18].
Especially novel strategies for the generation of recombinant Ro60
led to the availability of this antigen as a recombinant protein [4].
Recombinant antigen manufacturing is more consistent and less
dependent on the biological variations of the source material.
Based on the advances, recombinant proteins were the preferred
source of antigens for the development of the novel ENA7 screen.
Therefore, the novel CIA shows similar assay performance combined
with higher degree of consistency.
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Fig. 3. Receiver operating characteristic (ROC) analysis. ROC curves are shown for SARD a.), SLE b.), SSc c.), SjS d.), PM/DM e.), and PBC f.). Arrows indicate the cut-off values of CIA
and ELISA. The sensitivity and speciﬁcity of the CIA and the ELISA are similar in SARD (n = 427), SLE (n = 252), SSc (n = 64), SjS (n = 39), and PM/DM (n = 72).
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ELISA shows similar sensitivity, but much higher speciﬁcity compared
to ANA on HEp-2 in a large tertiary hospital reference laboratory [19].
In addition, apparent shifts in referral patterns away from specialists
[20] are increasing the inappropriate ordering and interpretation of
ANA testing [21].
Since we found 2 patients with anti-Scl-70 antibodies without
evidence of SSc we screened a large population of controls and found
high speciﬁcity, higher than previously reported in a meta-analysis
[2]. Several studies have nicely shown the presence of autoantibodies
before the clinical onset of SARD [22]. Some studies also reported the
evolution of SSc in patients initially diagnosed with primary SjS [23].Whether the anti-Scl-70 antibodies in those patients have clinical rele-
vance remains unclear.
Several studies have demonstrated limited sensitivity [24–26]
and speciﬁcity [12,27,28,28,29], of IIF on HEp-2 cells. Especially for
anti-Rib-P and anti-Ro antibodies, the IIF has been reported to
lack reliability [20,24–26]. In a comparative analysis of an ANA
ELISA and ANA IIF, equivalent sensitivity and speciﬁcity of the two
methods were observed [28]. Several studies have reported ANA
negative SLE [30,31]. In a study by Davis et al., 39 ANA negative
patients with detectable levels of ENA have been retrospectively
investigated and the majority of the patients were diagnosed as
having CTD [32]. It was found that adding of antigen speciﬁc assays
Table 4
Prevalence of autoantibodies in different disease cohorts.
Cohort n= ENA7 CIA
No (%) pos
ENA6 ELISA
No (%) pos
Systemic autoimmune rheumatic diseases 427 264 (61.8%) 267 (62.5%)
Systemic lupus erythematosus 252 157 (62.3%) 155 (61.5%)
Systemic sclerosis 64 35 (54.7%) 37 (57.8%)
Sjögren's syndrome 39 36 (92.3%) 35 (89.7%)
Polymyositis/dermatomyositis 72 36 (50.0%) 40 (55.6%)
Other diseases 605 30 (5.0%) 38 (6.3%)
Ankylosing spondylitis 13 1 (7.7%) 0 (0.0%)
Celiac disease 43 2 (4.7%) 3 (7.0%)
Degenerative spine disease 6 0 (0.0%) 0 (0.0%)
Fibromyalgia 5 0 (0.0%) 0 (0.0%)
Osteoarthritis 50 2 (4.0%) 3 (6.0%)
Rheumatoid arthritis 132 10 (7.6%) 9 (6.8%)
Inﬂammatory bowel disease 50 4 (8.0%) 4 (8.0%)
Hepatitis C virus 24 0 (0.0%) 7 (29.1%)
Hepatitis B virus 16 0 (0.0%) 1(6.3%)
Human immunodeﬁciency virus 7 0 (0.0%) 0 (0.0%)
Syphilis 6 0 (0.0%) 0 (0.0%)
Polymyalgia rheumatica 21 0 (0.0%) 1 (4.8%)
Psoriasis arthritis 14 0 (0.0%) 0 (0.0%)
Others 20 1 (5.0%) 1 (5.0%)
Vasculitis 2 0 (0.0%) 0 (0.0%)
Healthy individuals 196 10 (5.1%) 9 (4.6%)
Primary biliary cirrhosis 52 10 (19.2%) 6 (11.5%)
146 C. Bentow et al. / Clinica Chimica Acta 424 (2013) 141–147to IIF on HEp-2 cells signiﬁcantly improves the diagnostic algorithm
for the diagnosis of SARD [33]. However, it was concluded in this
study that changing from IIF to other methods for ANA detection
also requires modiﬁcation of the disease criteria. In addition, it
was highly recommended to use anti-Ro assays in addition to IIF
[33].
During the last 20 years several multiplex technologies have been
developed and used in laboratory medicine [10,34]. Among the earli-
est assays, line-immunoassays (LIA) can basically be considered as
second generation dot-blot assays. A broad range of LIAs are commer-
cially available and they are usually used to conﬁrm previous identi-
ﬁed autoantibodies. However, those assays might also have been
considered as a screening test for ANA or ENA [35]. Mainly manually
performed, these assays offer a simple way of multiplex testing and
even automated LIAs have become available [9]. Multiplex assays
based on the Luminex technology use addressable laser beads and
are therefore often referred to as ALBIA (addressable laser bead as-
says) [34]. Today several commercial ALBIA kits are available for the
detection of autoantibodies to nuclear antigens [11–13,29,36–40].
Similar to LIAs, the number of antigens and the antigen composition
signiﬁcantly vary. Multiplex assays are commonly used as a screening
test for anti-ENA/ANA or other autoantibodies. Usually the cost per
antibody test for those assays is lower compared to single analyte
testing, but more expensive than screening assays using a blend of
different antigens. Since most samples sent to a laboratory are nega-
tive [21] (consistent with our data; >90% were negative), screening
assays are mostly more cost-effective than multiplexing as screening
assays. This might be different in laboratories specialized in immunol-
ogy with high percentages of sample referrals from rheumatologists
and therefore with high positive rate.
More than 70% of anti-Jo-1 positive patients are also positive for
anti-Ro52. Besides anti-Ro52 antibodies, PM patients also have
other antibodies [4,16]. Thus the probability is b20% that anti-Jo-1
positive patients, i.e., 4% of all myositis patients are monospeciﬁc.
Therefore mono-speciﬁc samples had to be created to validate the
QUANTA Flash ENA7 CIA. Using this approach it has been demonstrat-
ed that the ENA7 CIA detects even low levels of anti-Jo-1 antibodies
and is therefore a reliable screening test for autoantibodies to all an-
tigens contained in the Screen.
Some studies reported antibodies to ENA in patients with PBC,
especially autoantibodies to antibodies Ro52 [8]. Based on theseﬁndings, we analyzed the utility of the ENA Screening assays for the
differentiation between PBC patients and controls. Although the dis-
crimination between the 2 groups was better using the QUANTA
Flash assay, anti-ENA antibodies in general might add signiﬁcant in-
formation to support the diagnosis of PBC. However, considering the
small number of patients and the low prevalence of anti-ENA anti-
bodies in PBC we acknowledge a limitation of this part of the study.
Further studies with large cohorts of PBC patients are necessary to
carefully evaluate the clinical utility of the ENA Screen for PBC.
5. Conclusion
Our data demonstrate that QUANTA Flash ENA7 is a reliable screen-
ing test for the rapid detection (30 min) of antibodies to RNP, Sm, Ro60,
Ro52, SS-B, Scl-70 and Jo-1. Using the reﬂex function of the software,
samples positive for anti-ENA antibodies can be reﬂexed and tested
for reactivity against the individual antigens.
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